Lymphovascular Invasion is Predictive for Adjuvant Platinum Therapy Benefit in Urothelial Bladder Cancer
This study demonstrates, for the first time, LVI status as a predictor of treatment benefit from platinum-based AC. Our results suggest that LVI status is an easily assessable biomarker to identify those patients who derive greater benefit from the treatment, while LVI-negative patients might be spared unnecessary chemotherapy and its associated toxicity.
Authors
- Eszter Székely
- Péter Nyírády (ORCID: https://orcid.org/0000-0002-7037-4919)
- Miklós Szűcs (ORCID: https://orcid.org/0000-0003-3576-8637)
- Ulrich Krafft (ORCID: https://orcid.org/0000-0002-0274-7445)
- Anita Csizmarik (ORCID: https://orcid.org/0000-0001-8394-3722)
- Tibor Szarvas (ORCID: https://orcid.org/0000-0002-6321-0799)
- Melinda Váradi (ORCID: https://orcid.org/0000-0001-7733-0831)
- Osama Mahmoud (ORCID: https://orcid.org/0000-0003-0342-6704)
- Boris Hadaschik (ORCID: https://orcid.org/0000-0002-1052-2692)
- András Kubik (ORCID: https://orcid.org/0000-0001-6901-9701)
- Mulham Al‐Nader (ORCID: https://orcid.org/0009-0006-7213-9417)
- D. Juhász
- Dániel Bacsó
Institutions
- Semmelweis University (HU)
- South Valley University (EG)
- West German Heart and Vascular Center Essen (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Clinical Genitourinary Cancer
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.clgc.2025.102421
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Innovációs és Technológiai Minisztérium
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap